uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis
Univ S Florida, H Lee Moffitt Canc Ctr, Dept Med, Tampa, FL 33682 USA..
Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Div Canc Med, Houston, TX 77030 USA..
Policlin Monza, Ist Oncol, Monza, Italy..
Novartis Int AG, Basel, Switzerland..
Show others and affiliations
2015 (English)In: Endocrine-Related Cancer, ISSN 1351-0088, E-ISSN 1479-6821, Vol. 22, no 6, 933-940 p.Article in journal (Refereed) PublishedText
Abstract [en]

Somatostatin analogues (SSA) have demonstrated antiproliferative activity in addition to efficacy for carcinoid symptom control in functional neuroendocrine tumors (NET). Apost hoc analysis of the placebo arm of the RAD001 In Advanced Neuroendocrine Tumors-2 (RADIANT-2) study was conducted to assess the efficacy of octreotide long-acting repeatable (LAR) on progression-free survival (PFS) and overall survival (OS) estimated using the Kaplan-Meier method. Out of 213 patients randomized to placebo plus octreotide LAR in RADIANT-2, 196 patients with foregut, midgut, or hindgut NETwere considered for present analysis. Of these, 41 patients were SSA-treatment naive and 155 had received SSA therapy before study entry. For SSA-naive patients, median PFS by adjudicated central review was 13.6 (95% CI 8.2-22.7) months. For SSA-naive patients with midgut NET (nZ24), median PFS was 22.2 (95% CI 8.3-29.5) months. For patients who had received SSA previously, the median PFS was 11.1 (95% CI 8.4-14.3) months. Among the SSA-pretreated patients who had midgut NET (nZ119), the median PFS was 12.0 (95% CI 8.4-19.3) months. Median OS was 35.8 (95% CI 32.5-48.9) months for patients in the placebo plus octreotide LAR arm; 50.6 (36.4 -not reached) months for SSA-naive patients and 33.5 (95% CI 27.5-44.7) months for those who had received prior SSA. This post hoc analysis of the placebo arm of the large phase 3 RADIANT-2 study provides data on PFS and OS among patients with progressive NET treated with octreotide therapy.

Place, publisher, year, edition, pages
2015. Vol. 22, no 6, 933-940 p.
Keyword [en]
neuroendocrine tumors, octreotide LAR, progression-free survival, somatostatin analogues
National Category
Cancer and Oncology
URN: urn:nbn:se:uu:diva-276881DOI: 10.1530/ERC-15-0314ISI: 000368230300018PubMedID: 26373569OAI: oai:DiVA.org:uu-276881DiVA: diva2:903694
Available from: 2016-02-16 Created: 2016-02-16 Last updated: 2016-02-16Bibliographically approved

Open Access in DiVA

fulltext(182 kB)24 downloads
File information
File name FULLTEXT01.pdfFile size 182 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Öberg, Kjell
By organisation
Department of Medical Sciences
In the same journal
Endocrine-Related Cancer
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 24 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 44 hits
ReferencesLink to record
Permanent link

Direct link